4 completed, 1 available, 1 terminated, 1 unknown. 4 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Terminated 1 |
Follow hydromethylthionine: new trials by email Literature Review of hydromethylthionine trials Research Report on hydromethylthionine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Application of Methylene Blue for Treatment of Covid-19 Patients MCN (Methylene blue, vitamin C, N-acetyl cysteine) - Covid-19 | Phase 1 | Unknown | Mashhad University of Medical Sciences | 20 | 2020-04-19 | 2020-05-04 |
| Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment TRx0237 16 mg/day, Control, TRx0237 8 mg/day - Alzheimer Disease | Phase 3 | Completed | TauRx Therapeutics Ltd | 598 | 2017-12-01 | 2025-09-04 |
| Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) TRx0237, Placebo - Behavioral Variant Frontotemporal Dementia (bvFTD) | Phase 3 | Completed | TauRx Therapeutics Ltd | 220 | 2013-05-01 | 2018-03-14 |
| Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease TRx0237 150 mg/day, TRx0237 250 mg/day, Placebo - Alzheimer's Disease | Phase 3 | Completed | TauRx Therapeutics Ltd | 891 | 2013-01-01 | 2018-03-14 |
| Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease TRx0237 200 mg/day, Placebo - Alzheimer's Disease | Phase 3 | Completed | TauRx Therapeutics Ltd | 800 | 2012-10-01 | 2018-03-14 |
| Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease TRx0237, Placebo - Alzheimer's Disease | Phase 2 | Terminated | TauRx Therapeutics Ltd | 9 | 2012-09-01 | 2014-07-11 |
| TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease TRx0237 - Alzheimer Disease | Available | TauRx Therapeutics Ltd | 2024-09-27 |
Alzheimer Disease (5) · Brain Diseases (2) · Dementia (2) · Neurodegenerative Diseases (2) · COVID-19 (1) · Coronavirus Infections (1) · Frontotemporal Dementia (1)
TauRx Therapeutics Ltd (6) · Mashhad University of Medical Sciences (1)
United Kingdom (5) · Canada (4) · Germany (4) · Italy (4) · Spain (4) · United States (4) · Australia (3) · Croatia (3) · Poland (3) · Belgium (2) · France (2) · Netherlands (2) · Romania (2) · Singapore (2) · Bulgaria (1)
Daryoush Hamidi Alamdari, Ph.D (1) · Mark Dale, MD (1)